• Explore /
  • Poster
  • / KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Abstract Poster

Authors

null

Yung-Jue Bang

Seoul National University Hospital, Seoul, Republic of Korea

Yung-Jue Bang , Kei Muro , Charles S. Fuchs , Talia Golan , Ravit Geva , Hiroki Hara , Shadia Ibrahim Jalal , Christophe Borg , Toshihiko Doi , Zev A. Wainberg , Jiangdian Wang , Minori Koshiji , Rita P. Dalal , Hyun Cheol Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02335411

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4012)

DOI

10.1200/JCO.2017.35.15_suppl.4012

Abstract #

4012

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Sun Young Rha

First Author: Josep Tabernero

First Author: Zev A. Wainberg

First Author: Charles S. Fuchs